Search results for "urokinase"

showing 10 items of 36 documents

Annexin A2-Mediated Plasminogen Activation in Endothelial Cells Contributes to the Proangiogenic Effect of Adenosine A2A Receptors

2021

Adenosine A2A receptor mediates the promotion of wound healing and revascularization of injured tissue, in healthy and animals with impaired wound healing, through a mechanism depending upon tissue plasminogen activator (tPA), a component of the fibrinolytic system. In order to evaluate the contribution of plasmin generation in the proangiogenic effect of adenosine A2A receptor activation, we determined the expression and secretion of t-PA, urokinase plasminogen activator (uPA), plasminogen activator inhibitor-1 (PAI-1) and annexin A2 by human dermal microvascular endothelial cells stimulated by the selective agonist CGS-21680. The plasmin generation was assayed through an enzymatic assay a…

0301 basic medicineFarmacologiaAngiogenesisPlasminmedicine.medical_treatmentVasodilatadorsAdenosine A2A receptorRM1-950030204 cardiovascular system & hematologyTissue plasminogen activatormicrovascular endothelial cells03 medical and health scienceschemistry.chemical_compound0302 clinical medicineFibrinolysismedicinePharmacology (medical)urokinase plasminogen activatorPharmacologytissue plasminogen activatorChemistryBrief Research Reportannexin A2adenosine receptorsCell biology030104 developmental biologyPlasminogen activator inhibitor-1plasminogen activator inhibitor-1Therapeutics. PharmacologyPlasminogen activatorProteïnesAnnexin A2medicine.drug
researchProduct

Proteolytic Enzymes Clustered in Specialized Plasma-Membrane Domains Drive Endothelial Cells’ Migration

2016

In vitro cultured endothelial cells forming a continuous monolayer establish stable cell-cell contacts and acquire a "resting" phenotype; on the other hand, when growing in sparse conditions these cells acquire a migratory phenotype and invade the empty area of the culture. Culturing cells in different conditions, we compared expression and clustering of proteolytic enzymes in cells having migratory versus stationary behavior. In order to observe resting and migrating cells in the same microscopic field, a continuous cell monolayer was wounded. Increased expression of proteolytic enzymes was evident in cell membranes of migrating cells especially at sprouting sites and in shed membrane vesi…

0301 basic medicinekalininsepraseCell Membranesbeta1 integrinCelllcsh:MedicineurokinaseBiochemistryEpitheliumCell membrane0302 clinical medicineAnimal CellsMedicine and Health Sciencesdipeptidyl peptidase IVlcsh:ScienceMultidisciplinarybiologyVesicleProteolytic enzymesCell migrationProteasesEnzymesCell biologyLaboratory EquipmentCell Motilitymedicine.anatomical_structureBiochemistry030220 oncology & carcinogenesisEngineering and TechnologyBiological Culturesmatrix metalloproteinase 14Cellular Structures and OrganellesCellular TypesAnatomyResearch ArticleEquipmentCell MigrationResearch and Analysis MethodsGelatin MediaCell Linegelatinase B03 medical and health sciencescollagen type 4fibronectinmedicineHumansVesiclescollagen type 1gelatinase Alcsh:RCell MembraneBiology and Life SciencesEndothelial CellsProteinsMembrane ProteinsEpithelial CellsCell BiologyCulture MediaFibronectinBiological Tissue030104 developmental biologyMembrane proteinCell cultureProteolysisMicroscopy Electron ScanningEnzymologybiology.proteinlcsh:QCollagensDevelopmental BiologyPLOS ONE
researchProduct

Systematic Analysis of Combined Thrombolysis Using Ultrasound and Different Fibrinolytic Drugs in an in Vitro Clot Model of Intracerebral Hemorrhage.

2021

Adequate removal of blood clots by minimally invasive surgery seems to correlate with a better clinical outcome in patients with intracerebral hemorrhages (ICHs). Moreover, neurotoxic effects of recombinant tissue plasminogen activator have been reported. The aim of this study was to improve fibrinolysis using an intra-clot ultrasound application with tenecteplase and urokinase in our established ICH clot model. One hundred thirty clots were produced from 25 or 50 mL of human blood, incubated for different periods and equipped with drainage, through which an ultrasound catheter was placed in 65 treatment clots for 1 h, randomly allocated into three groups: administration of ultrasound, admi…

Acoustics and UltrasonicsMechanical Thrombolysismedicine.medical_treatmentUltrasonic TherapyBiophysicsTenecteplase030204 cardiovascular system & hematologyIn Vitro Techniques03 medical and health sciences0302 clinical medicineFibrinolytic AgentsFibrinolysismedicineHumansRadiology Nuclear Medicine and imagingThrombolytic TherapyCerebral HemorrhageIntracerebral hemorrhageUrokinaseRadiological and Ultrasound Technologybusiness.industryUltrasoundThrombosisThrombolysismedicine.diseaseCombined Modality TherapyUrokinase-Type Plasminogen ActivatorIn vitroCatheterAnesthesiaTenecteplasebusiness030217 neurology & neurosurgerymedicine.drugUltrasound in medicinebiology
researchProduct

Blood coagulation factor XII drives adaptive immunity during neuroinflammation via CD87-mediated modulation of dendritic cells

2016

Aberrant immune responses represent the underlying cause of central nervous system (CNS) autoimmunity, including multiple sclerosis (MS). Recent evidence implicated the crosstalk between coagulation and immunity in CNS autoimmunity. Here we identify coagulation factor XII (FXII), the initiator of the intrinsic coagulation cascade and the kallikrein–kinin system, as a specific immune cell modulator. High levels of FXII activity are present in the plasma of MS patients during relapse. Deficiency or pharmacologic blockade of FXII renders mice less susceptible to experimental autoimmune encephalomyelitis (a model of MS) and is accompanied by reduced numbers of interleukin-17A-producing T cells.…

AdultMale0301 basic medicineEncephalomyelitis Autoimmune ExperimentalMultiple Sclerosisanimal structuresT-LymphocytesScienceMedizinGeneral Physics and AstronomyKininsCoagulation Factor XIIAdaptive ImmunityBiologymedicine.disease_causeArticleGeneral Biochemistry Genetics and Molecular BiologyReceptors Urokinase Plasminogen ActivatorAutoimmunityYoung Adult03 medical and health sciencesImmune systemddc:570medicineAnimalsHumansddc:610cardiovascular diseasesNeuroinflammationAgedFactor XIIMultidisciplinaryInterleukin-17QExperimental autoimmune encephalomyelitisCell DifferentiationDendritic CellsGeneral ChemistryMiddle Agedmedicine.diseaseAcquired immune systemMice Inbred C57BL030104 developmental biologyNeuroimmunologyFactor XIIImmunologyFemaleKallikreinscirculatory and respiratory physiologyNature Communications
researchProduct

Prognostic value of soluble urokinase plasminogen activator receptor in patients presenting to the emergency department with chest pain suggestive of…

2021

International audience; INTRODUCTION: Soluble urokinase plasminogen activator receptor (suPAR) is a prognostic biomarker of cardiovascular disease. OBJECTIVES: We aimed to evaluate the early prognostic value of suPAR in patients presenting to the emergency department (ED) with chest pain suggestive of acute coronary syndrome (ACS). PATIENTS AND METHODS: In a post-hoc analysis from a multicenter study including patients with a chest pain < 6 h, suPAR concentrations at ED admission were studied according to the outcome at 30-days. RESULTS: 198 patients (median age 56 years) in whom 16% had an ACS, were included. Fifteen (7.3%) patients presented a 30-day event. At ED admission, median (IQR…

AdultMale030213 general clinical medicineAcute coronary syndromemedicine.medical_specialty[SDV]Life Sciences [q-bio]Clinical BiochemistrySoluble urokinase plasminogen activator receptorDisease030204 cardiovascular system & hematologyChest painPrognosticGastroenterologyReceptors Urokinase Plasminogen ActivatorsuPARChest pain03 medical and health sciences0302 clinical medicinePredictive Value of TestsInternal medicinemedicineHumansIn patientAcute Coronary SyndromeReceptorAgedOutcomeAged 80 and overbusiness.industryEmergency departmentGeneral MedicineEmergency departmentMiddle Agedmedicine.diseasePrognosisED30-day event3. Good health[SDV] Life Sciences [q-bio]SuPARBiomarker (medicine)Femalemedicine.symptombusinessEmergency Service HospitalBiomarkers
researchProduct

Effects of acute exercise and allopurinol administration on soluble urokinase plasminogen activator receptor (suPAR).

2013

Background Although physical exercise acutely increases the most widely used inflammatory biomarkers, there is no information on its effect on soluble urokinase plasminogen activating receptor (suPAR), a circulating biomarker increasingly used for the assessment of systemic inflammation. Methods suPAR was assessed with the quantitative suPARnostic Standard ELISA Assay (Virogates, Birkerod, Denmark) in 12 professional football players before and after a football match. The athletes were divided into two experimental groups. An oral dose of 300 mg of allopurinol was administered to one group of six participants four hours before a match; the other six participants received placebo. Results Se…

AdultMalemedicine.medical_specialtyacute exercise; allopurinol; suPARAllopurinolPhysical exerciseEnzyme-Linked Immunosorbent AssayallopurinolPlaceboSystemic inflammationacute exerciseGastroenterologyGeneral Biochemistry Genetics and Molecular BiologySuparnosticReceptors Urokinase Plasminogen ActivatorsuPARPlaceboschemistry.chemical_compoundInternal medicinemedicineHumansEnzyme InhibitorsXanthine oxidaseExerciseUrokinasebusiness.industrychemistrySuPARmedicine.symptombusinessmedicine.drug
researchProduct

Pharmacological thrombolysis: one more weapon for free-flap salvage.

2005

Despite the high success rate of free-tissue transfer, thrombosis still complicates 5-30% of cases. Meticoulous technique, careful vessel selection, and pharmacological prophylaxis are not always enough to avoid thrombosis. Early diagnosis and reintervention provide the only way to salvage a thrombosed free flap, in case of either arterial or venous thrombosis. When kinking, torsion, or external compression of the pedicle are ruled out, and thrombectomy and redo of the anastomosis are unsuccessful, the last resort to save the flap is thrombolytic therapy. The authors present their experience with the salvage of two otherwise lost flaps by means of urokinase thrombolysis through direct intra…

AdultMalemedicine.medical_specialtymedicine.medical_treatmentFree flapAnastomosisTHERAPYSurgical FlapsMICROVASCULAR SURGERYFibrinolysismedicineMANAGEMENTHumansThrombolytic TherapyVeinUrokinaseAged 80 and overVenous Thrombosisbusiness.industrySTREPTOKINASE SALVAGEGraft SurvivalThrombolysisTHROMBECTOMYmedicine.diseaseThrombosisUrokinase-Type Plasminogen ActivatorSurgeryVenous thrombosismedicine.anatomical_structureSurgerybusinessmedicine.drugMicrosurgery
researchProduct

In vitro Analysis of Synergistic Effects of Fibrinolytic Agents and Prostacyclin Analogues

1997

We investigated the in vitro thrombolytic effects of streptoki-nase, urokinase, alteplase and saruplase, alone or in combination, with the prostacyclin analogues, iloprost and taprostene. Human platelet-rich plasma was stimulated with collagen (1 μg/ml) to generate thrombi containing platelets and fibrin. Following treatment with fibrinolytic agents, lysis was allowed to proceed for 30 min and was then terminated with aprotinin (2,000 ClU/ml). To evaluate the combinatory effects of fibrinolytic agents and prostacyclin analogues, we used concentrations of fibrinolytic agents which reduced thrombi weight by less than 50%. Neither iloprost nor taprostene alone demonstrated any thrombolytic eff…

AdultMalemedicine.medical_treatmentProstacyclinPharmacologyFibrinolytic AgentsPhysiology (medical)Prostaglandins SyntheticFibrinolysismedicineHumansStreptokinaseIloprostUrokinaseChemistryFibrinolysisDrug SynergismHematologyDrug interactionEpoprostenolUrokinase-Type Plasminogen ActivatorIn vitroTissue Plasminogen Activatorcardiovascular systemFemaleSaruplaseFibrinolytic agentIloprostmedicine.drugPathophysiology of Haemostasis and Thrombosis
researchProduct

MicroRNA expression profile in endometriosis: its relation to angiogenesis and fibrinolytic factors

2014

Study question Could an aberrant microRNA (miRNA) expression profile be responsible for the changes in the angiogenic and fibrinolytic states observed in endometriotic lesions? Summary answer This study revealed characteristic miRNA expression profiles associated with endometriosis in endometrial tissue and endometriotic lesions from the same patient and their correlation with the most important angiogenic and fibrinolytic factors. WHAT IS ALREADY KNOWN?: An important role for dysregulated miRNA expression in the pathogenesis of endometriosis is well documented. However, to the best of our knowledge, there are no reports of the relationship between angiogenic and fibrinolytic factors and mi…

AdultVascular Endothelial Growth Factor Amedicine.medical_specialtyAngiogenesisEndometriosisEndometriosisEndometriumThrombospondin 1EndometriumYoung Adultchemistry.chemical_compoundInternal medicinePlasminogen Activator Inhibitor 1microRNAmedicineHumansNeovascularization Pathologicbusiness.industryRehabilitationObstetrics and GynecologyMicroRNA Expression ProfileMiddle Agedmedicine.diseaseUrokinase-Type Plasminogen ActivatorVascular endothelial growth factorMicroRNAsVascular endothelial growth factor AEndocrinologymedicine.anatomical_structureReproductive MedicinechemistryCase-Control StudiesCancer researchFemalebusinessFibrinolytic agentHuman Reproduction
researchProduct

Fibrinolytic parameters in normotensive pregnancy with intrauterine fetal growth retardation and in severe preeclampsia

1991

In pregnancy a decrease in fibrinolytic activity, which is due to an increase in plasminogen activator inhibitor activity and plasminogen activator inhibitor type 1 and type 2, has been described. Because the placenta is a source of both type 1 and type 2 plasminogen activator inhibitor, we have studied them and other fibrinolytic parameters in a group of normotensive pregnant women with intrauterine fetal growth retardation and in two groups of women with preeclampsia, with or without intrauterine growth retardation. A significant increase in plasminogen activator inhibitor type 1 antigen and plasminogen activator inhibitor activity was observed in preeclampsia, with or without intrauterin…

Adultmedicine.medical_specialtymedicine.medical_treatmentBlood PressurePreeclampsiaPre-EclampsiaAntigenPregnancyReference ValuesInternal medicinePlacentaFibrinolysismedicineFetal growthHumansPregnancyFetal Growth Retardationbusiness.industryFibrinolysisObstetrics and Gynecologymedicine.diseaseUrokinase-Type Plasminogen ActivatorPathophysiologyPlasminogen Inactivatorsmedicine.anatomical_structureEndocrinologyTissue Plasminogen ActivatorImmunologyFemalebusinessPlasminogen activatorAmerican Journal of Obstetrics and Gynecology
researchProduct